Better Together: BioCryst, Idera Merge To Improve Rare Disease Position

22 Jan 2018

New company will have pair of Phase III candidates, an immuno-oncology licensing opportunity, strong experience in hereditary angioedema and roughly $243m in cash to position itself as a rare disease stronghold.

A pair of primarily clinical-stage, publicly traded rare disease biotechs – BioCryst Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. – are merging in an all-stock transaction to create a larger firm that will have a stronger mid- and late-stage pipeline, an R&D organization with expertise in small molecules and oligonucleotides, and a significant stockpile of cash.

Together, the to-be-named new company will have novel, orally administered Phase III and Phase II candidates for hereditary angioedema (HAE),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

04 Jun 2025

• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.